Parkinson's disease
Conditions
Interventions
Control group:sham acupuncture
Sponsors
The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
50 Years to 75 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1.Age between 50 and 75 years; 2.No acupuncture treatment received within 3 months prior to enrollment; 3.No adjustment to the anti-Parkinson's disease (PD) medication regimen within 3 months prior to enrollment; 4.Score of =1 on the rigidity subscale of the Movement Disorder Society–Unified Parkinson's Disease Rating Scale (MDS-UPDRS); 5.Hoehn and Yahr stage 1–3 (i.e., patients with early-to-moderate Parkinson's disease); 6.Clinically diagnosed with Parkinson's disease; 7.Having clear consciousness, providing signed informed consent, agreeing to receive the treatment protocol and complete the full course of the study, and willing to cooperate in completing the rating scales.
Exclusion criteria
Exclusion criteria: Exclusion criteria: 1.Failure to meet any one of the above inclusion criteria; 2.Presence of musculoskeletal comorbidities that may affect gait assessment, specifically including: a. residual functional impairment following healed fractures of the lumbosacral spine, pelvis, or bilateral lower limbs; b. moderate-to-severe organic lesions (confirmed by imaging) in any of the hip, knee, or ankle joints; c. history of spinal or lower limb surgery within 1 year prior to enrollment; 3.Presence of definite severe systemic diseases, such as immune system disorders, endocrine system disorders (e.g., pheochromocytoma, hyperthyroidism, etc.), respiratory diseases, cardiovascular or cerebrovascular diseases, or hepatic/renal insufficiency; 4.Presence of other conditions that may clearly cause parkinsonism or are suspected to be related to the patient's symptoms, such as Parkinson-plus syndromes, essential tremor, etc.; 5.Presence of definite cerebellar ataxia or cerebellar oculomotor abnormalities; 6.Presence of definite cortical sensory loss, limb ideomotor apraxia, or progressive aphasia; 7.Presence of downward vertical supranuclear gaze palsy or selective slowing of downward vertical saccades; 8.Diagnosis of highly suspected behavioral variant frontotemporal dementia or primary progressive aphasia within 5 years of disease onset; 9.Lack of significant therapeutic response to high-dose levodopa treatment; 10.History of definite psychiatric disorders or presence of psychotic symptoms, such as depression, schizophrenia, etc.; 11.History of substance abuse (e.g., alcohol, drugs, caffeine) within the past 6 months, or history of taking hypnotics or psychotropic medications; 12.Participation in other clinical trials (including drug trials, acupuncture trials, etc.) within 1 month prior to enrollment in this study; 13.Fear of acupuncture; 14.Presence of orthostatic hypotension.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MDS-UPDRS rigidity score; | — |
Secondary
| Measure | Time frame |
|---|---|
| MDS Unified Parkinson's Disease Rating Scale;Falls Efficacy Scale - International;Zarit Burden Interview;Lindop Parkinson's Physiotherapy Assessment Scale (LPAS) ;Parkinson's Disease Questionnaire-39;Instrumented Gait Analysis; Electromyography;Electroencephalography; | — |
Countries
China
Contacts
Public ContactJingqi Fan
The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Outcome results
None listed